Aelis Farma Reports Its 2022 Annual Financial Results and Confirms Its 2023 Outlook – Medical Marijuana Program Connection

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announced its annual results for the year to December 31, 2022. Pier Vincenzo Piazza, CEO of Aelis Farma, said: “2022 was marked by a number of key events for Aelis Farma, beginning with our IPO, which enabled us to raise substantial financial resour

Source link